News

The organizations and their full-time employees both benefited from the PRN IPs.

The newly approved therapy will use the brand name, Brexafemme, and is a one-day, novel, oral treatment for vaginal yeast infection.

A significant decrease in the rate of VAP occurred during the study period.

Post-intervention saw 55% of patients receive overall guideline-concordant antibiotics.

Nonspecific, nondolent symptoms make this disease difficult to diagnose.

The Sinovac developed vaccine generated antibodies against SARS-CoV-2 in a phase 1/2 trial.

Sensors provided data for more hand washing opportunities for healthcare workers and affected related behaviors.

The CAD demonstrated excellent sustained antiviral activity against the test pathogen.

Average annual discharges were significantly higher in participating hospitals.

Investigators apply guidelines into practical management strategies.

During the pandemic, one regional health system looked at the age distribution of the virus and hospitalization and mortality rates.

AstraZeneca’s COVID-19 vaccine was safe and immunogenic for people with HIV who are well-controlled on antiretroviral therapy, a study has shown.

New model uses syndromic surveillance to predict admissions related to SARS-CoV-2.

The therapy is known to exhibit antiviral properties and reduce SARS-CoV-2 replication in laboratory studies.

Seqirus is seeking reactogenicity and immunogenicity outcomes between its influenza vaccines and available mRNA vaccines for COVID-19.

Plus: how could the COVID-19 testing market boom improve public flu awareness?

Recommendations based on local pollen levels may help manage infection risk.

The challenging search for a metric that effectively evaluates an ASP’s direct impact on appropriate antimicrobial use and improved patient outcomes.

As many vaccines are under Emergency Use Authorization (EUA), understanding the incidence rates of adverse events is critical to providing education and awareness, while working to increase distribution.

A preview of our August 2021 issue Chairman’s Letter.

The organizations set out 3 recommendations for initial and recurrent C diff treatment.

An interview with a study author on new Novavax-Seqirus co-administration trial data, and the future concerns of circulating COIVD-19 and influenza.

Delta Plus is very similar to the Delta variant with 1 additional mutation.

With a small number of heart-related adverse effects in younger people, the US Food and Drug Administration (FDA) will move towards a warning statement for Pfizer and Moderna vaccines.

More treatment options and modalities are now available for patients.

A new report from a Qatari pilot program showed vaccines are highly effective against COVID-19, but they do not completely eliminate risk.

The benefits of mRNA vaccinations were determined to still clearly outweigh the risks in adolescents and young adults.

New ASM data show indoor environments are associated with quick and frequent pathogen contamination of the common respiratory device.